Safety and Effectiveness of Direct-Acting Antiviral Agents for Treatment of Patients With Chronic Hepatitis C Virus Infection and Cirrhosis  Raoel Maan, Marjolein van Tilborg, Katja Deterding, Alnoor Ramji, Adriaan J. van der Meer, Florence Wong, Scott Fung, Morris Sherman, Michael P. Manns, Markus Cornberg, Bettina E. Hansen, Heiner Wedemeyer, Harry L.A. Janssen, Robert J. de Knegt, Jordan J. Feld  Clinical Gastroenterology and Hepatology  Volume 14, Issue 12, Pages 1821-1830.e6 (December 2016) DOI: 10.1016/j.cgh.2016.07.001 Copyright © 2016 AGA Institute Terms and Conditions

Figure 1 Kaplan–Meier curves showing the occurrence of hepatic decompensation from the start of therapy to SVR12 for 4 important baseline factors. Straight lines represent the first event; dotted lines represent subsequent events. Among patients with a Child–Pugh score of A, there were no subsequent events. The 24-week cumulative incidence for the first event was as follows: (A) Child–Pugh score of A, 1.9% (95% CI, 0.3–3.5); Child–Pugh score of B/C, 34.5% (95% CI, 25.7–43.3); (B) MELD score less than 14, 5.3% (95% CI, 2.9–7.7); MELD score of 14 or greater, 39.4% (95% CI, 27.6–51.2); (C) albumin level of 35 g/L or greater, 3.4% (95% CI, 1.2–5.6); albumin level less than 35 g/L, 22.2% (95% CI, 15.7–28.7); and (D) HCV genotype non-3, 8.7% (95% CI, 5.8–11.6); HCV genotype 3, 19.2% (95% CI, 10.2–28.2). Clinical Gastroenterology and Hepatology 2016 14, 1821-1830.e6DOI: (10.1016/j.cgh.2016.07.001) Copyright © 2016 AGA Institute Terms and Conditions

Figure 2 Change in MELD score at the SVR12 visit for all patients and patients with a Child–Pugh score of B/C. Patients who underwent liver transplantation, died, or were lost to follow-up evaluation were not included. (A) Changes in MELD score for patients who achieved SVR and (B) changes in MELD score for patients who did not attain SVR. Gray bars represent improvement of MELD score and black bars represent worsening of MELD score. *Number of patients (%) with a significant change in MELD score (ie, ≥2 points). Clinical Gastroenterology and Hepatology 2016 14, 1821-1830.e6DOI: (10.1016/j.cgh.2016.07.001) Copyright © 2016 AGA Institute Terms and Conditions

Supplementary Figure 1 Flow chart for hepatic decompensation from start of therapy to the SVR12 visit. In total, 50 patients experienced at least 1 decompensating event. In 19 (38%) patients a subsequent decompensating event was reported. HE, hepatic encephalopathy. Clinical Gastroenterology and Hepatology 2016 14, 1821-1830.e6DOI: (10.1016/j.cgh.2016.07.001) Copyright © 2016 AGA Institute Terms and Conditions